Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAmortizationAndAccretionNet.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Net loss | $(43,320) | $(64,387) |
| Adjustment to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 5,485 | 2,271 |
| Amortization/Accretion of bond discounts/premiums | (559) | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (2,561) | (1,591) |
| Other assets | 37 | — |
| Accounts payable | 2,807 | 582 |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s D&A?
- ArriVent BioPharma, Inc. (AVBP) reported D&A of -$559K in Q1 2026.
- How has ArriVent BioPharma, Inc.'s D&A changed year-over-year?
- ArriVent BioPharma, Inc.'s D&A increased by 26.1% year-over-year, from -$756.5K to -$559K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about ArriVent BioPharma, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude